Challenges and prospects for pharmacotherapy in functional gastrointestinal disorders

Gareth J. Sanger, Chang Lin Chang, Chas Bountra, Lesley A. Houghton

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Functional gastrointestinal disorders, such as irritable bowel syndrome and functional dyspepsia, are complex conditions with multiple factors contributing to their pathophysiology. As a consequence they are difficult to treat and have posed significant challenges to the pharmaceutical industry when trying to develop new and effective treatments. This review provides an overview of these difficulties and how the industry is reshaping its drug developmental strategies. It describes some of the more significant and encouraging advances that have occurred, and discusses how future research might embrace the opportunities provided by advances in genetic and in particular, epigenetic research.

Original languageEnglish (US)
Pages (from-to)291-305
Number of pages15
JournalTherapeutic Advances in Gastroenterology
Volume3
Issue number5
DOIs
StatePublished - Sep 2010
Externally publishedYes

Fingerprint

Irritable Bowel Syndrome
Gastrointestinal Diseases
Dyspepsia
Drug Industry
Epigenomics
Industry
Drug Therapy
Research
Pharmaceutical Preparations
Therapeutics

Keywords

  • animal models
  • epigenetics
  • IBS
  • mechanisms
  • pharmacotherapy

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Challenges and prospects for pharmacotherapy in functional gastrointestinal disorders. / Sanger, Gareth J.; Lin Chang, Chang; Bountra, Chas; Houghton, Lesley A.

In: Therapeutic Advances in Gastroenterology, Vol. 3, No. 5, 09.2010, p. 291-305.

Research output: Contribution to journalArticle

Sanger, Gareth J. ; Lin Chang, Chang ; Bountra, Chas ; Houghton, Lesley A. / Challenges and prospects for pharmacotherapy in functional gastrointestinal disorders. In: Therapeutic Advances in Gastroenterology. 2010 ; Vol. 3, No. 5. pp. 291-305.
@article{c308a52830d643a1a6c03e43985c8a0a,
title = "Challenges and prospects for pharmacotherapy in functional gastrointestinal disorders",
abstract = "Functional gastrointestinal disorders, such as irritable bowel syndrome and functional dyspepsia, are complex conditions with multiple factors contributing to their pathophysiology. As a consequence they are difficult to treat and have posed significant challenges to the pharmaceutical industry when trying to develop new and effective treatments. This review provides an overview of these difficulties and how the industry is reshaping its drug developmental strategies. It describes some of the more significant and encouraging advances that have occurred, and discusses how future research might embrace the opportunities provided by advances in genetic and in particular, epigenetic research.",
keywords = "animal models, epigenetics, IBS, mechanisms, pharmacotherapy",
author = "Sanger, {Gareth J.} and {Lin Chang}, Chang and Chas Bountra and Houghton, {Lesley A.}",
year = "2010",
month = "9",
doi = "10.1177/1756283X10369922",
language = "English (US)",
volume = "3",
pages = "291--305",
journal = "Therapeutic Advances in Gastroenterology",
issn = "1756-283X",
publisher = "SAGE Publications Ltd",
number = "5",

}

TY - JOUR

T1 - Challenges and prospects for pharmacotherapy in functional gastrointestinal disorders

AU - Sanger, Gareth J.

AU - Lin Chang, Chang

AU - Bountra, Chas

AU - Houghton, Lesley A.

PY - 2010/9

Y1 - 2010/9

N2 - Functional gastrointestinal disorders, such as irritable bowel syndrome and functional dyspepsia, are complex conditions with multiple factors contributing to their pathophysiology. As a consequence they are difficult to treat and have posed significant challenges to the pharmaceutical industry when trying to develop new and effective treatments. This review provides an overview of these difficulties and how the industry is reshaping its drug developmental strategies. It describes some of the more significant and encouraging advances that have occurred, and discusses how future research might embrace the opportunities provided by advances in genetic and in particular, epigenetic research.

AB - Functional gastrointestinal disorders, such as irritable bowel syndrome and functional dyspepsia, are complex conditions with multiple factors contributing to their pathophysiology. As a consequence they are difficult to treat and have posed significant challenges to the pharmaceutical industry when trying to develop new and effective treatments. This review provides an overview of these difficulties and how the industry is reshaping its drug developmental strategies. It describes some of the more significant and encouraging advances that have occurred, and discusses how future research might embrace the opportunities provided by advances in genetic and in particular, epigenetic research.

KW - animal models

KW - epigenetics

KW - IBS

KW - mechanisms

KW - pharmacotherapy

UR - http://www.scopus.com/inward/record.url?scp=77956237154&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956237154&partnerID=8YFLogxK

U2 - 10.1177/1756283X10369922

DO - 10.1177/1756283X10369922

M3 - Article

VL - 3

SP - 291

EP - 305

JO - Therapeutic Advances in Gastroenterology

JF - Therapeutic Advances in Gastroenterology

SN - 1756-283X

IS - 5

ER -